In contrast, there was no significant difference in progression between non-CD5-T-cell marker-positive DLBCL and T-cell marker-negative DLBCL, suggesting that T-cell markers other than CD5 do not have prognostic impacts in DLBCL treated by immuno-chemotherapy (Figure 3). Here, CD5 is linked to diffuse large B-cell lymphoma.